AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7351151
Drug: Atropine sulphate
RxNorm normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulphate (0.08 mg/kg) administered by inhalation, four times a day for seven days
Trial: 7351151
Drug: Isoproterenol hydrochloride
RxNorm normalized name: Isoproterenol Hydrochloride
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoproterenol hydrochloride (2.5 mg) administered by inhalation, four times a day for seven days
Trial: 31831561
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of choice (TC; topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)
Trial: 31831561
Drug: Guadecitabine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guadecitabine and carboplatin (G+C)
Trial: 31831561
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of choice (TC)
Trial: 31146679
Drug: LVPEG-4 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVPEG-4 (1 L preparation + 1 L required additional fluid)
Trial: 31146679
Drug: Control (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (2 L PEG + Asc)
Trial: 27869451
Drug: Internet-delivered family-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered family-based cognitive-behavioral therapy (FB-CBT)
Trial: 27869451
Drug: Clinic-based family-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic-based family-based cognitive-behavioral therapy (FB-CBT)
Trial: 27566295
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug therapy (AAD)
Trial: 24363933
Drug: Current medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current medications only (Control)
Trial: 12513901
Drug: Directly administered
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly administered antiretroviral therapy (DAART)
Trial: 15156431
Drug: Treatment-adherence support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-adherence support
Trial: 11270011
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection technique with 20 mL of ropivacaine 0.75%
Trial: 2147517
Drug: paroxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paroxetine (30 mg/day)
Trial: 15780704
Drug: venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: venlafaxine XR (225 mg/day)
Trial: 31035478
Drug: 140 mL
RxNorm normalized name: syringe, disposable, 140 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mL of concentrated beetroot juice (800 mg NO3‐)
Trial: 31618208
Drug: Intensive anthelminthic
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive anthelminthic treatment
Trial: 25902705
Drug: Standard anthelminthic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anthelminthic treatment
Trial: 24195204
Drug: Bleeding and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleeding and cupping therapy, applied locally with pricking and cupping once every two days for a total of 8 treatments.
Trial: 24195204
Drug: Pregabalin, 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin, 150mg orally, twice a day for a total of 16 days.
Trial: 19091808
Drug: Clinical practice
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical practice (first attending clinical physician's treatment)
Trial: 16541783
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg x kg(‐1) LCT/MCT propofol
Trial: 16541783
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg x kg(‐1) LCT propofol
Trial: 16541783
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg x kg(‐1) LCT/MCT propofol
Trial: 10792202
Drug: Ceftazidime 40
RxNorm normalized name: CEFTAZIDIME 40ML/ML INJ,50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 40 mg kg‐1 8 hourly by bolus injection
Trial: 10792202
Drug: Ceftazidime 4
RxNorm normalized name: CEFTAZIDIME 40ML/ML INJ,50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 4 mg kg‐1 h‐1 by constant infusion following a 12 mg kg‐1 priming dose
Trial: 9186297
Drug: Tolrestat treatment
RxNorm normalized name: tolrestat
DrugBank: Tolrestat (DB02383)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolrestat treatment for 4 weeks in 17 patients
Trial: 9186297
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 4 weeks in 17 patients
Trial: 3525423
Drug: Viminol R2
RxNorm normalized name: viminol
DrugBank: Viminol (DB13353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viminol R2 10 mg
Trial: 31008736
Drug: Pentazocine 30
RxNorm normalized name: pentazocine 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 30 mg
Trial: 24734891
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (Lis)
Trial: 25739586
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (Asp)
Trial: 12571667
Drug: Isoflavone supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone supplementation (Novasoy, 50 mg daily of isoflavone equivalents)
Trial: 1575787
Drug: Monthly telephone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly telephone contact by lay personnel
Trial: 27997877
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion (0.02 μg kg‐1 min‐1)
Trial: 27129091
Drug: Total glucosides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total glucosides of paeony capsule (TGPC) combined with corticosteroids
Trial: 10553817
Drug: Tight control
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight control of blood glucose with a standardized IV insulin infusion (Group TC)
Trial: 6601648
Drug: Rifaprim (RPM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaprim (RPM) - 800 mg SMZ + 160 mg TMP twice daily
Trial: 21682350
Drug: DRV/r monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/r monotherapy
Trial: 25247995
Drug: IPTp-MQ (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPTp-MQ (15 mg/kg)
Trial: 22573627
Drug: Lubiprostone (Amitiza)
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lubiprostone (Amitiza) titrated up to 48 μg/day
Trial: 20332739
Drug: Propofol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.5 mg.kg-1 + ketamine 0.5 mg.kg-1
Trial: 20332739
Drug: Propofol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.5 mg.kg-1 + ketamine 0.25 mg.kg-1
Trial: 12077156
Drug: Cefpodoxime 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpodoxime 400 mg
Trial: 29624558
Drug: Cefixime 400
RxNorm normalized name: cefixime 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 400 mg
Trial: 29128558
Drug: 35% CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% CO2 inhalation
Trial: 10401916
Drug: Compressed air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compressed air inhalation
Trial: 19046724
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/day
Trial: 19111075
Drug: TENS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS treatment (5 times per week for 4 weeks, 60 Hz, 100 microS, 25 mA, 20 minutes)
Trial: 28125513
Drug: DC vaccine
RxNorm normalized name: Recombinant chimeric COVID-19 DC vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC vaccine
Trial: 16038528
Drug: Control (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (chemotherapy only)
Trial: 6603654
Drug: Trimethoprim and
RxNorm normalized name: Trimethoprim and derivatives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim and methenamine hippurate (TMP + MH) at 100 + 500 mg b.i.d.
Trial: 27829445
Drug: Community-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based intervention program integrating HIV-testing and treatment services, ECCD, and nutrition education for caregivers, consisting of nine group-based sessions over 12 weeks.
Trial: 2125242
Drug: Selegiline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (10 mg once daily)
Trial: 6778330
Drug: Oral decongestant
RxNorm normalized name: Drixoral Decongestant Non-Drowsy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral decongestant (pseudoephedrine hydrochloride)
Trial: 6778330
Drug: Decongestant-antihistamine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongestant-antihistamine combination (pseudoephedrine hydrochloride and chlorpheniramine maleate)
Trial: 17303249
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (control group).
Trial: 10336003
Drug: TT virus
RxNorm normalized name: rubella virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TT virus DNA detection in donors with elevated ALT levels (mean ALT 89.3 U/L)
Trial: 10336003
Drug: TT virus
RxNorm normalized name: rubella virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TT virus DNA detection in donors with normal ALT levels (<= 45 U/L)
Trial: 7487244
Drug: Enalaprilat 0.625
RxNorm normalized name: enalaprilat 0.625 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat 0.625 mg
Trial: 7487244
Drug: Enalaprilat 1.25
RxNorm normalized name: enalaprilat 1.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat 1.25 mg
Trial: 1337458
Drug: Enalaprilat 2.5
RxNorm normalized name: enalaprilat 2.5 MG per 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat 2.5 mg
Trial: 7487244
Drug: Enalaprilat 5
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalaprilat 5 mg
Trial: 7487244
Drug: Enalaprilat (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat (all doses)
Trial: 1793725
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with electrically stimulated lymphatic drainage (group B)
Trial: 7074796
Drug: Dobutamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine treatment (4-hour infusions weekly for 24 weeks)
Trial: 31816038
Drug: Empagliflozin (E)
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin (E) 10 mg with Linagliptin (L) 5 mg once daily
Trial: 31816038
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (M) 850 or 1000 mg twice daily with Insulin Glargine (I) once daily
Trial: 20578537
Drug: Albendazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (15 mg/kg/day for 3 days)
Trial: 3971104
Drug: Prophylactic intravenous
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intravenous mezlocillin
Trial: 30451243
Drug: Bupivacaine 0.125%/fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.125%/fentanyl 5.0 μg/mL
Trial: 30451243
Drug: Ropivacaine 0.2%/fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2%/fentanyl 5.0 μg/mL
Trial: 28224463
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg
Trial: 15280147
Drug: Acidic vaginal
RxNorm normalized name: Acidic Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acidic vaginal gel (Miphil)
Trial: 1336892
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg administered as a single daily dose for 3 days)
Trial: 1336892
Drug: Amoxycillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanic acid (50 mg/kg/day given b.i.d. for 10 days)
Trial: 10647800
Drug: Intravenous methylnaltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous methylnaltrexone
Trial: 21978432
Drug: Acellular human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular human dermal matrix augmentation (GraftJacket)
Trial: 31173130
Drug: No augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No augmentation
Trial: 23210068
Drug: Midazolam 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.075 mg/kg
Trial: 8089543
Drug: Prednisolone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (10 mg orally three times a day)
Trial: 24168840
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy Scale (CTS)
Trial: 24168840
Drug: ACE Treatment
RxNorm normalized name: Acet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE Treatment Integrity Measure (ATIM)
Trial: 21703000
Drug: Telephone administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone administration of CRIS measure
Trial: 21703000
Drug: In-person administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-person administration of CRIS measure
Trial: 14996470
Drug: Non-Aspirin
RxNorm normalized name: Non-Aspirin
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Aspirin
Trial: 11555764
Drug: Nebulized topical
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized topical saline‐tobramycin solution administered thrice daily for 4 weeks
Trial: 11555764
Drug: Saline‐only solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline‐only solution administered thrice daily for 4 weeks
Trial: 3327930
Drug: Nicardipine (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (0.06 mg/min)
Trial: 3793001
Drug: Domperidone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (10 mg i.v.)
Trial: 24668360
Drug: Usual daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual daily activities (control group)
Trial: 27079993
Drug: Psychiatrists' ability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatrists' ability to provide inpatient and other treatments
Trial: 25467772
Drug: Community paramedic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community paramedic intervention (regular home visits, health assessments, evidence-based treatments)
Trial: 15599642
Drug: Saline, 3
RxNorm normalized name: Simply Saline, 3% nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline, 3 intra-articular injections of 2 ml saline at the same intervals (10 knees)
Trial: 10985480
Drug: IFNalpha 2b
RxNorm normalized name: Zenalpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNalpha 2b (5 MU sqm/daily)
Trial: 10985480
Drug: IFNalpha 2b
RxNorm normalized name: Zenalpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNalpha 2b plus low-dose AraC
Trial: 10985480
Drug: IFNalpha/AraC therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNalpha/AraC therapy
Trial: 8803740
Drug: Educational videotape
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational videotape about PSA testing and treatment uncertainties (N = 184 in study 1, N = 103 in study 2)
Trial: 6424229
Drug: Cimetidine (05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (05 mg/kg/h) after an initial bolus of 1.5 mg/kg
Trial: 28865249
Drug: Ultra-low-dose HT
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose HT (0.5 mg 17β‐estradiol/2.5 mg dydrogesterone)
Trial: 28865249
Drug: Standard HT
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard HT (1 mg 17β‐estradiol/5 mg dydrogesterone)
Trial: 25617253
Drug: Aripiprazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (2 mg per day for days 1-2, 5 mg per day for days 3-4, 10 mg per day for days 5-7, flexibly dosed 5, 10, or 15 mg per day from week 2 to end of study)
Trial: 17425158
Drug: Weight-adjusted unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-adjusted unfractionated heparin (Heparin-'Biochemie' 25.000 IU/5 ml)
Trial: 11807634
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g plus gentamicin 5 mg/kg
Trial: 11807634
Drug: Cefepime 2
RxNorm normalized name: cefepime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 2 g t.i.d. plus gentamicin 5 mg/kg q.d.
Trial: 7589023
Drug: Molsidomine 4
RxNorm normalized name: molsidomine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine 4 mg (2 tablets, given 6 h apart)
Trial: 225750
Drug: Diluent control
RxNorm normalized name: DILUENT
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diluent control solution
Trial: 225750
Drug: MSH/ACTH 4-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSH/ACTH 4-10 (30 mg)
Trial: 22763473
Drug: Cilnidipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilnidipine (10 mg per day titrated to 20 mg per day)
Trial: 22763473
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg per day titrated to 10 mg per day)
Trial: 20571820
Drug: Cabergoline 0.5
RxNorm normalized name: cabergoline 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.5 mg twice per week for 8 weeks
Trial: 20571820
Drug: Cabergoline 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.25 mg twice per week for 8 weeks
Trial: 20571820
Drug: Cabergoline 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.125 mg twice per week for 8 weeks
Trial: 20571820
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance treatment (Group I)
Trial: 17962596
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg pravastatin for 2 weeks followed by 40 mg for 4 weeks
Trial: 7575754
Drug: Sustained-release tablet
RxNorm normalized name: Oratuss 12 Sustained-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release tablet (C)
Trial: 6972824
Drug: Phenoprocoumon (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenoprocoumon (oral anticoagulation) starting on the seventh postoperative day
Trial: 29767694
Drug: Serum α-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum α-carotene levels (per log unit (μg/dL) increase)
Trial: 29767694
Drug: Serum α-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum α-carotene concentrations at or above the US average (2.92 μg/dL)
Trial: 18204133
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg HFA‐BDP once daily (o.d.)
Trial: 18204133
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg HFA‐BDP twice daily (b.i.d.)
Trial: 16179873
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m) plus treosulfan (2500 or 3000 mg/m2) in cohort 1
Trial: 16179873
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m) plus treosulfan (3500 or 4000 mg/m2) in cohort 2
Trial: 16179873
Drug: Cohort 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1 (treosulfan dose <=3000 mg/m2)
Trial: 16179873
Drug: Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2 (treosulfan dose >=3500 mg/m2)
Trial: 12114041
Drug: Fel d
RxNorm normalized name: Anti-cat allergen fel d 1 monoclonal anitbody regn-1908
DrugBank: Freneslerbart (DB19080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fel d 1 peptides (90 microg in increasing divided doses)
Trial: 10220224
Drug: Immunocytochemistry with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunocytochemistry with antibodies recognizing NR1 or NR2A/B subunits
Trial: 7787130
Drug: Dolasetron mesylate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron mesylate, single IV doses ranging from 0.30 to 0.60 mg kg‐1 on day 1
Trial: 7787130
Drug: Dolasetron mesylate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron mesylate, multiple IV doses ranging from 0.60 to 1.20 mg kg‐1 d‐1 on days 2-9
Trial: 381954
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 50 mg once or twice daily
Trial: 23811305
Drug: HIGH-dose steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIGH-dose steroid (prednisolone 5mg/kg/day, n=44)